Twist Bioscience (TWST) News Today

Shares of Twist Bioscience Corporation (NASDAQ:TWST) have seen movement today amid a combination of analyst upgrades, technical signals and fresh guidance on earnings. Key factors include:

• Positive Sentiment: Equities researcher Leerink Partnrs raised its FY2025 EPS estimate for TWST from ($2.24) to ($2.12), reflecting moderating losses and improving operating trends. Leerink Partnrs Has Positive Outlook of TWST FY2025 Earnings
• Positive Sentiment: William Blair also lifted its FY2025 EPS forecast, moving from a loss of ($2.14) to ($1.98) per share, underscoring growing confidence in the company’s revenue ramp. What is William Blair's Forecast for TWST FY2025 Earnings?
• Positive Sentiment: Zacks noted that TWST has entered technically oversold territory after a recent pullback, suggesting the stock could be ripe for a rebound if selling pressure subsides. After Plunging 33.8% in 4 Weeks, Here’s Why the Trend Might Reverse for Twist Bioscience (TWST)
• Neutral Sentiment: A recent survey of healthcare analysts placed Twist Bioscience alongside peers like Moderna with a neutral consensus, indicating mixed expectations on near-term catalysts. Analysts Are Neutral on These Healthcare Stocks: Moderna (MRNA), Twist Bioscience (TWST)
• Negative Sentiment: Twist Bioscience recently hit a new 12-month low amid continued selling pressure, prompting some market watchers to question whether it’s time to exit the position. Twist Bioscience (NASDAQ:TWST) Sets New 12-Month Low - Time to Sell?